Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906164 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL6480252 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL12224193 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL23795276 | 0.79 | KMT2A (0.51) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL23795282 | 0.79 | KMT2A (0.51) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL10253668 | 0.78 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL22395252 | 0.78 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL12352042 | 0.78 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL15759500 | 0.78 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL22623891 | 0.77 | KMT2A (0.56) | KMT2AMEN1NPSR1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1027 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20200179248-A1 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | claimed |
| WO-2018182509-A1 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-10-04 | — | — | WO | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| EP-2007394-B1 | NOVEL USE OF ANTIHISTAMINE AGENTS FOR THE PREVENTIVE OR EARLY TREATMENT OF INFLAMMATORY SYNDROMES, IN PARTICULAR THOSE TRIGGERED BY TOGAVIRUSES | PF MEDICAMENT (FR) | 2012-10-10 | — | — | EP | claimed |
| WO-2012116278-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| EP-0687172-B1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 2002-12-04 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6207178-B1 | STABLE SUSPENSION | KABI PHARMACIA AB (SE) | 2001-03-27 | — | — | US | claimed |
| US-5785976-A | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | PHARMACIA & UPJOHN AB (SE) | 1998-07-28 | — | — | US | claimed |
| EP-0687172-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | Pharmacia & Upjohn Aktiebolag (SE) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020072-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 1994-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | KMT2A 3867/4885MEN1 2829/4885NPSR1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.